Fecal transplant for radiation-induced rectal bleeding
Treatments studied
Part of Digestive system clinical trials.
This study tests whether a fecal (stool) transplant can help heal rectal damage caused by pelvic radiation. The treatment may decrease bleeding and improve symptoms for people whose supportive care hasn't worked well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You finished pelvic radiation at least 3 months ago and your cancer has not returned or spread
- You have rectal bleeding (moderate to severe) that has not gotten better with standard care, or your hemoglobin is very low
- A colonoscopy showed that your rectum lining is red, swollen, or has abnormal blood vessels
- You do not have serious infections, bleeding disorders, a colostomy, or a bowel blockage
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a dietary supplement to help heal damage inside the rectum caused by pelvic radiation therapy. If you have mild to moderate rectal bleeding but no signs of cancer recurrence, you may be able to join.
This trial studies whether fecal microbiota transplantation (FMT)—a medical procedure using stool from a screened donor to restore gut bacteria—can improve safety and outcomes for people with certain bowel, immune, and metabolic conditions. It may help if your symptoms are thought to be related to an unhealthy gut microbiome, though eligibility is broad and depends on specific safety factors.
This trial tests whether transferring healthy bacteria from a donor's stool (called fecal microbiota transplantation) can improve bowel problems like frequent bowel movements or trouble controlling gas or stool, which are common after rectal cancer surgery. The goal is to see if this treatment helps you feel better and improves your quality of life.
This early-phase study tests whether stool/fecal microbiota transplant (a fecal transplant) can help people who develop significant diarrhea or colitis after immune-checkpoint therapy. It aims to reduce bowel inflammation and improve symptoms, while carefully checking for infections.
This study tests a combination of fecal microbiota transplant, chemotherapy, radiation, and immunotherapy (sintilimab) for people with locally advanced rectal cancer. The goal is to see if this approach improves treatment outcomes.
This study tests whether giving patients healthy donor stool bacteria (fecal microbiota transplantation) can reduce or prevent nausea, diarrhea, and other stomach or bowel problems caused by cancer treatment. It is for people with extrapulmonary neuroendocrine tumors who have had gastrointestinal side effects during their first three treatment cycles.
Hear when a new Radiation Induced Proctitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.